BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting being held November 16-19, 2023 in Vancouver, Canada.

BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director.

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced it has been recognized with the “Therapeutics Platform Of The Year” award in the third annual BioTech Breakthrough Awards program.

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming INV€$TIVAL Showcase in partnership with Jefferies, being held on November 13, 2023 in London, United Kingdom. 

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming Pharma Partnering Summit in Boston October 19-20, 2023. At the meeting, BPGbio’s President and CEO, Dr. Niven R. Narain, and Executive Chairman Daniel Elliott will unveil the progress made in advancing their oncology drug candidate BPM31510, currently under investigation for glioblastoma multiforme (GBM) and pancreatic cancer. They will also provide insights into the company’s growing portfolio of AI-discovered therapeutics and diagnostics, identified through the company’s proprietary NAi Interrogative Biology® Platform.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.